Nuo Therapeutics, Inc. Quarterly Common Stock, Shares Authorized from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Nuo Therapeutics, Inc. quarterly Common Stock, Shares Authorized history and growth rate from Q4 2010 to Q3 2024.
  • Nuo Therapeutics, Inc. Common Stock, Shares Authorized for the quarter ending September 30, 2024 was 100M shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 100M 0 0% Sep 30, 2024 10-Q 2024-11-12
Q2 2024 100M 0 0% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 100M 0 0% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 100M 0 0% Dec 31, 2023 10-Q 2024-11-12
Q3 2023 100M 0 0% Sep 30, 2023 10-Q 2023-11-20
Q2 2023 100M 0 0% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 100M 0 0% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 100M 0 0% Dec 31, 2022 10-K 2024-04-19
Q3 2022 100M 0 0% Sep 30, 2022 10-Q 2022-11-04
Q2 2022 100M 0 0% Jun 30, 2022 10-Q/A 2022-08-10
Q1 2022 100M 0 0% Mar 31, 2022 10-Q 2022-05-16
Q4 2021 100M 0 0% Dec 31, 2021 10-K 2023-04-17
Q3 2021 100M 0 0% Sep 30, 2021 10-Q 2022-11-04
Q2 2021 100M 0 0% Jun 30, 2021 10-K 2022-04-15
Q1 2021 100M 0 0% Mar 31, 2021 10-K 2022-04-15
Q4 2020 100M 0 0% Dec 31, 2020 10-Q 2022-11-04
Q3 2020 100M 0 0% Sep 30, 2020 10-K 2022-04-15
Q2 2020 100M 0 0% Jun 30, 2020 10-K 2022-04-15
Q1 2020 100M 0 0% Mar 31, 2020 10-K 2022-04-15
Q4 2019 100M 0 0% Dec 31, 2019 10-K 2022-04-15
Q3 2019 100M 0 0% Sep 30, 2019 10-Q 2020-01-31
Q2 2019 100M +68.5M +217% Jun 30, 2019 10-Q 2019-08-19
Q1 2019 100M +68.5M +217% Mar 31, 2019 10-Q 2019-05-20
Q4 2018 100M 0 0% Dec 31, 2018 10-Q 2020-01-31
Q3 2018 100M +68.5M +217% Sep 30, 2018 10-Q 2018-11-16
Q2 2018 31.5M 0 0% Jun 30, 2018 10-Q 2018-08-13
Q1 2018 31.5M 0 0% Mar 31, 2018 10-Q 2018-05-14
Q4 2017 100M +68.5M +217% Dec 31, 2017 10-K 2019-04-16
Q3 2017 31.5M 0 0% Sep 30, 2017 10-Q 2017-11-13
Q2 2017 31.5M 0 0% Jun 30, 2017 10-Q 2017-08-14
Q1 2017 31.5M -394M -92.6% Mar 31, 2017 10-Q 2017-05-15
Q4 2016 31.5M -394M -92.6% Dec 31, 2016 10-K 2018-04-16
Q3 2016 31.5M -394M -92.6% Sep 30, 2016 10-Q 2016-11-14
Q2 2016 31.5M -394M -92.6% Jun 30, 2016 10-Q 2016-10-24
Q1 2016 425M 0 0% Mar 31, 2016 10-Q 2016-10-24
Q4 2015 425M 0 0% Dec 31, 2015 10-K 2017-03-29
Q3 2015 425M 0 0% Sep 30, 2015 10-Q 2015-11-13
Q2 2015 425M 0 0% Jun 30, 2015 10-Q 2015-08-13
Q1 2015 425M +225M +113% Mar 31, 2015 10-Q 2015-05-14
Q4 2014 425M +225M +113% Dec 31, 2014 10-K 2016-10-24
Q3 2014 425M +225M +113% Sep 30, 2014 10-Q 2014-11-13
Q2 2014 425M +225M +113% Jun 30, 2014 10-Q 2014-08-14
Q1 2014 200M +40M +25% Mar 31, 2014 10-Q 2014-05-15
Q4 2013 200M 0 0% Dec 31, 2013 10-K 2015-03-31
Q3 2013 200M +40M +25% Sep 30, 2013 10-Q 2013-11-12
Q2 2013 200M +40M +25% Jun 30, 2013 10-Q 2013-08-08
Q1 2013 160M +60M +60% Mar 31, 2013 10-Q 2013-05-09
Q4 2012 200M +40M +25% Dec 31, 2012 10-K 2014-03-31
Q3 2012 160M +60M +60% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 160M +60M +60% Jun 30, 2012 10-Q 2012-08-14
Q1 2012 100M Mar 31, 2012 10-Q 2012-05-15
Q4 2011 160M +60M +60% Dec 31, 2011 10-K 2013-03-18
Q3 2011 100M Sep 30, 2011 10-Q 2011-11-14
Q2 2011 100M Jun 30, 2011 10-Q 2011-08-15
Q4 2010 100M Dec 31, 2010 10-K 2012-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.